Nuvation Bio Inc. NUVB
4.16 USD -0.03 (-0.72%)
At closeNov 6, 2026, 6:45 PM EST
4.19 +0.03 +0.72%
After hours · Nov 6, 6:45 PM ET
3.98 Day range 4.33
4.05 52-week range 9.54
- YTD
- -53.57%
- 1 year
- -17.13%
- Market cap
- 1.47B
- Revenue (ttm)
- 201.73M
- Profit margin
- -67.38%
- EPS (ttm)
- -0.39
- Shares out
- 352.02M
- Forward P/E
- -276.67
- YTD return
- -53.57%
- 1-year return
- -17.13%
- Volume
- 5.34M
- Avg volume
- 5.38M
- Open
- 4.21
- Previous close
- 4.19
- Day's range
- 3.98 – 4.33
- 52-week range
- 4.05 – 9.54
- Analysts
- Strong Buy
- Price target
- 13.00 (+212.5%)
- Earnings date
- Mar 1, 2027
5D -0.68 (-14.05%)
Key statistics
- Enterprise value
- 1.28B
- PEG ratio
- 0.00
- Price / sales
- 7.26
- Price / book
- 6.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 242.60%
- Free cash flow
- -77.72M
- Total cash
- 663.37M
- Total debt
- 468.12M
- Return on equity
- -49.09%
- Short % of float
- 29.40%
- 50-day average
- 5.44
- 200-day average
- 5.37
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.00 +212.5% upside
Now 4.16
- Target (low)
- 7.00
- Target (mean)
- 13.00
- Target (high)
- 21.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy3
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -0.09.
Financials — quick view
NUVB Revenue — quarterly 44.95M
NUVB Net income — quarterly -41.90M
NUVB EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | -0.10 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.12357 | -0.12 | 0.00 | +2.89% |
| Aug 6, 2026 | Jun 30, 2026 | -0.14166 | -0.15 | -0.01 | -5.89% |
| May 4, 2026 | Mar 31, 2026 | -0.02804 | 0.01 | +0.04 | +135.66% |
| Mar 2, 2026 | Dec 31, 2025 | -0.11 | -0.11 | 0.00 | 0.00% |
| Nov 3, 2025 | Sep 30, 2025 | -0.17 | -0.16 | +0.01 | +5.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 30, 2026 | Citigroup | init | — | Buy |
| Sep 16, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Sep 16, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 21, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 18, 2026 | JP Morgan | init | — | Overweight |
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nuvationbio.com
News
12 Health Care Stocks Moving In Thursday's After-Market Session 
RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17 
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript 
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates 
Nuvation Bio Q3 2026 Earnings Call Transcript 
Nuvation Bio Q3 EPS $(0.12), Inline, Sales $44.951M Beat $34.224M Estimate 
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 
Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting 
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting 
Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib
Your note
Sign in to keep a note on NUVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HANLEY DAVID C | Chief Technology Officer | Sale | Nov 18, 2025 | 24,000 |
| HUNG DAVID T | Chief Executive Officer | Purchase | Jun 15, 2025 | 59,281,100 |
| LIU DONGFANG | Officer | Sale | Apr 16, 2026 | 18,000 |
| MAKUNJE MOSES | Officer | Stock Award(Grant) | Feb 26, 2026 | 68,137 |
| MARKEL STACY | Officer | Sale | Jun 22, 2026 | 32,591 |
| MASHAL ROBERT | Director | Purchase | Jun 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.88% | 52,230,295 | 216.76M | Jun 29, 2026 |
| Blackrock Inc. | 7.87% | 27,630,837 | 114.67M | Jun 29, 2026 |
| Decheng Capital LLC | 7.39% | 25,954,439 | 107.71M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.39% | 11,919,514 | 49.47M | Jun 29, 2026 |
| Omega Fund Management, Llc | 2.30% | 8,081,089 | 33.54M | Jun 29, 2026 |
| Laurion Capital Management, LP | 2.19% | 7,697,272 | 31.94M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.05% | 17,725,175 | 73.56M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 8,849,329 | 36.72M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.86% | 6,523,172 | 27.07M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.42% | 4,993,377 | 20.72M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.30% | 4,568,601 | 18.96M | Sep 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.98% | 3,423,823 | 14.21M | Sep 29, 2026 |